You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
拓新藥業(301089.SZ):積極開展合成生物學相關技術在核苷、核苷酸類產品領域的應用研究
格隆匯 05-08 19:30

格隆匯5月8日丨拓新藥業(301089.SZ)公佈股票交易異常波動公吿,近期,公司關注到網絡及部分媒體發佈了關於“合成生物學”的相關報道。合成生物學以系統生物學和工程學原理為指導,將基因組和生化分子合成作為核心技術,通過生物化學、生物物理和生物信息學等技術,不斷設計、改造、重塑生物分子、生物元件和生物分化過程,為構建具有生命活性的生物元件、系統以及人造細胞或生物體奠定堅實基礎。在醫療健康領域,合成生物學的應用廣泛且前景廣闊。目前公司積極開展合成生物學相關技術在核苷、核苷酸類產品領域的應用研究,相關技術應用於部分產品的生產,2023年度,該類產品實現的收入佔營業收入的比例不足5%,佔比較低,未來發展情況具有較大的不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account